| Literature DB >> 23144343 |
Nadia Nathan1, Emmanuelle Girodon, Annick Clement, Harriet Corvol.
Abstract
We report the case of a 12-year-old girl with an allergic bronchopulmonary aspergillosis (ABPA), intermediate sweat chloride tests and one cystic fibrosis (CF)-causing mutation, p.Phe508del. After extensive screening of the CF transmembrane regulator (CFTR) gene, she finally was found to carry a rare deep intronic mutation (c.872-1110_1113delGAAT), which confirmed the atypical mild CF disease. Although a classical steroid treatment did not allow the healing of the ABPA, an omalizumab therapy led to a long-term recovery. This case emphasises the need to search for rare CFTR gene mutations as far as possible when a CF disease is evocated. Moreover, it also highlights that although omalizumab is not yet recognised as a classical ABPA treatment in CF, it should be considered as an alternative therapy in steroid-resistant patients.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23144343 PMCID: PMC4543918 DOI: 10.1136/bcr-2012-006918
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X